Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 dose escalation study of XMT-2056

Next Previous
X
Search
Trial Profile

A Phase 1 dose escalation study of XMT-2056

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XMT-2056 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Mersana Therapeutics

    • Most Recent Events

    • 09 May 2024 According to a Mersana Therapeutics media release,Status changed from planning to recruiting.
    • 09 May 2024 According to a Mersana Therapeutics media release, In the first quarter of 2024, Mersana reopened clinical sites and resumed patient recruitment
    • 28 Feb 2024 According to a Mersana Therapeutics media release, the company is looking forward for collaborations with Johnson & Johnson and Merck KGaA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top